회사 개요
Koninklijke Philips N.V. operates as a comprehensive health technology entity with a global footprint spanning North America, Greater China, and international markets, delivering solutions across Diagnosis & Treatment, Connected Care, and Personal Health segments. The company is firmly established within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on capital-intensive manufacturing and rigorous regulatory compliance essential for life-saving equipment. This operational scale is reflected in a total market capitalization of $25.67B and annual revenue generation of $17.83B, supported by an employee base of 61,085 individuals. These valuation and revenue figures indicate that the company maintains a significant position within the healthcare ecosystem, possessing substantial assets and a large workforce capable of sustaining operations across diverse geographic regions.
재무 건전성
The company reported a total revenue of $17.83B over the trailing twelve months, generating a net income of $899.00M and an EBITDA of $2.02B, where the substantial gap between revenue and net income highlights a significant cost structure comprising operating expenses, taxes, and interest obligations that absorb approximately 95% of top-line earnings. Free cash flow stands at $453.00M, indicating that after capital expenditures, the entity retains sufficient liquidity to fund operations, service debt, or potentially return capital, though the margin between EBITDA and free cash flow suggests heavy investment requirements or working capital needs. Profitability metrics reveal a gross margin of 45.2%, an operating margin of 10.7%, and a profit margin of 5.0%, collectively demonstrating that while the cost of goods sold is controlled, the final ability to convert sales into profit is moderated by high overhead costs typical in the medical device sector. The balance sheet shows a cash position of $2.79B against total debt of $8.09B, resulting in a debt-to-equity ratio of 73.57, which characterizes the firm as moderately leveraged given that debt obligations significantly exceed liquid cash reserves. Short-term liquidity is assessed via a current ratio of 1.32, suggesting the company holds enough current assets to cover current liabilities with a modest safety buffer. Return metrics further illustrate management effectiveness, with a return on equity of 7.8% and a return on assets of 3.2%, indicating that the company generates modest returns relative to the capital employed and shareholders' equity.
밸류에이션 평가
Valuation multiples show a trailing P/E ratio of 25.03 and a forward P/E of 12.84, where the wide divergence implies that the market expects a significant expansion in future earnings that is not yet reflected in current profitability levels. The price-to-book ratio is 2.01, indicating that the market values the company at more than double its book value, suggesting investors are willing to pay a premium for the intangible assets, brand reputation, and growth potential inherent in the medical device sector. Alternative valuation metrics include a price-to-sales ratio of 1.44 and an EV/EBITDA of 15.28, which provide a broader perspective on value relative to revenue generation and operating cash earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range between a low of $21.48 and a high of $33.44, and without a specific current price listed in the provided facts, the valuation context relies on these historical extremes to gauge relative positioning. The beta value of 0.94 indicates that the stock's price volatility is nearly identical to the broader market, meaning it moves in tandem with general market fluctuations without exhibiting excessive aggression or defensiveness.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 1.1%, while earnings growth data is marked as N/A in the available facts, preventing a direct comparison of earnings velocity against revenue expansion but highlighting the need to monitor future profitability trends carefully. Regarding income distribution, the company offers a dividend yield of 3.8% with a payout ratio of 91.7%, which suggests that nearly all net income is distributed to shareholders rather than retained for reinvestment. Such a high payout ratio implies that the company prioritizes shareholder returns through dividends, potentially limiting internal funding for research and development or organic growth initiatives compared to peers with lower payout obligations. The overall growth and income profile presents a mature company delivering steady cash returns through a robust dividend yield rather than rapid capital appreciation or aggressive earnings expansion.